GALT: Gunggung utang perusahaan Galectin

This chart illustrates that the market value of Galectin Therapeutics (GALT), which specializes in liver disease therapy, is 0.00. Galectin Therapeutics (GALT) is systematically deploying its existing capital to fund the launch of cirrhosis trials. While its fibrosis research is protected by copyright, the high probability of failure in the final stages requires a constant influx of investment for the issuer.

Galectin Therapeutics, Inc. - Utang perusahaan GALT (periode 04.07.2022 - 28.10.2026)

Rincian analitis lan laporan data perusahaan Galectin Therapeutics (GALT)

- rega lan prakiraan konsensus rega:

Bagan owah-owahan rega galectintherapeutics.com|GALT - Prakiraan konsensus analis

- data kapitalisasi pasar:

Kapitalisasi pasar Galectin|GALT - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi Saham Galectin Therapeutics|GALT - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Aset Bersih galectintherapeutics.com|GALT - Total Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Galectin Therapeutics|GALT - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal galectintherapeutics.com|GALT - Utang perusahaan|Rasio utang marang kapitalisasi buku Galectin|GALT - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Galectin Therapeutics

Analisis fundamental perusahaan:GALT Galectin Therapeutics, Inc.

This indicator aggregates total bank loans and bond issuances, reflecting the issuer's overall debt load. By analyzing the business's total liabilities, an investor determines the balance between financial leverage and insolvency risk. A decrease in the metric indicates capital strengthening, while an increase signals expansion. For Galectin Therapeutics (GALT), debt capital serves as a funding tool for research. The development of liver fibrosis drugs remains independent of macroeconomic cycles.

Pesaing wigati

Kewajiban utang agregat Arrowhead Corp (ARWR)|Gunggung utang perusahaan MIRM (Mirum Pharmaceuticals)|Dynavax Pharma - Gunggung utang perusahaan|Utang perusahaan Arbutus Biopharma Corporation (ABUS)|IVA: Kewajiban utang agregat|GYRE (Gyre Corp) - Utang perusahaan|Assembly Corp (ASMB) - Gunggung utang perusahaan|GNFT (Genfit SA) - Gunggung utang perusahaan|Gunggung utang perusahaan DURECT Corp. (DRRX)|Aligos Therapeutics (ALGS) - Gunggung utang perusahaan|Kewajiban utang agregat BIVI (biovieinc.com)|Utang perusahaan Galmed Pharmaceuticals Ltd. GLMD|Utang perusahaan ENDRA Corp NDRA|Gunggung utang perusahaan HEPA (Hepion Pharma)